Quintiles Transitional Holdings (Q) : 8 brokerage houses believe that Quintiles Transitional Holdings (Q) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Quintiles Transitional Holdings (Q). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 12 Wall Street Analysts endorse the stock as a Buy with a rating of 1.54.
Quintiles Transitional Holdings (Q) stock is expected to deviate a maximum of $5.02 from the average target price of $79.35 for the short term period. 10 Street Experts have initiated coverage on the stock with the most promising target being $87 and the most muted being $71.
For the current week, the company shares have a recommendation consensus of Buy.
Quintiles Transitional Holdings (NYSE:Q): The stock opened at $77.66 on Wednesday but the bulls could not build on the opening and the stock topped out at $77.85 for the day. The stock traded down to $76.86 during the day, due to lack of any buying support eventually closed down at $77.04 with a loss of -0.67% for the day. The stock had closed at $77.56 on the previous day. The total traded volume was 1,119,688 shares.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.